Latest news with #MajaPataki
Business Insider
15-05-2025
- Business
- Business Insider
Analysts Offer Insights on Healthcare Companies: Alcon (ALC) and Innate Pharma SA (OtherIPHYF)
Analysts fell to the sidelines weighing in on Alcon (ALC – Research Report) and Innate Pharma SA (IPHYF – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks. Confident Investing Starts Here: Alcon (ALC) Kepler Capital analyst Maja Pataki maintained a Hold rating on Alcon on May 13 and set a price target of CHF88.00. The company's shares closed last Wednesday at $87.24. According to Pataki has 0 stars on 0-5 stars ranking scale with an average return of -13.6% and a 33.6% success rate. Pataki covers the Healthcare sector, focusing on stocks such as Tecan Group AG, Demant, and Qiagen. Currently, the analyst consensus on Alcon is a Strong Buy with an average price target of $110.11. Innate Pharma SA (IPHYF) Kepler Capital analyst Justine Telliez maintained a Hold rating on Innate Pharma SA on May 13 and set a price target of EUR3.10. The company's shares closed last Friday at $1.45, close to its 52-week low of $1.28.
Business Insider
11-05-2025
- Business
- Business Insider
Kepler Capital Sticks to Their Hold Rating for Coloplast A/S (0QBO)
Kepler Capital analyst Maja Pataki maintained a Hold rating on Coloplast A/S (0QBO – Research Report) on May 9 and set a price target of DKK715.00. The company's shares closed last Friday at DKK643.92. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. Pataki covers the Healthcare sector, focusing on stocks such as Tecan Group AG, Alcon, and Demant. According to TipRanks, Pataki has an average return of -13.7% and a 33.76% success rate on recommended stocks. In addition to Kepler Capital , Coloplast A/S also received a Hold from RBC Capital's Jack Reynolds-Clark in a report issued on May 9. However, on May 7, Morgan Stanley maintained a Sell rating on Coloplast A/S (LSE: 0QBO).
Business Insider
04-05-2025
- Business
- Business Insider
Kepler Capital Remains a Hold on Coloplast A/S (0QBO)
In a report released on May 2, Maja Pataki from Kepler Capital maintained a Hold rating on Coloplast A/S (0QBO – Research Report), with a price target of DKK870.00. The company's shares closed last Friday at DKK699.84. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. According to TipRanks, Pataki is an analyst with an average return of -14.0% and a 32.77% success rate. Pataki covers the Healthcare sector, focusing on stocks such as Tecan Group AG, Alcon, and Demant. Coloplast A/S has an analyst consensus of Hold, with a price target consensus of DKK849.00.
